Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
lymphoid leukemia | — | D007945 | C91 |
Expiration | Code | ||
---|---|---|---|
ofatumumab, Arzerra, Novartis Pharmaceuticals Corporation | |||
2123-01-19 | Orphan excl. |
Code | Description |
---|---|
J9302 | Injection, ofatumumab, 10 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 2 | 9 | 8 | 33 | 52 |
Sclerosis | D012598 | — | — | — | 2 | 9 | 8 | 29 | 48 |
Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 1 | 6 | 6 | 11 | 24 |
Covid-19 | D000086382 | — | U07.1 | — | — | — | 1 | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 3 | 6 | 4 | — | — | 13 |
Leukemia | D007938 | — | C95 | 3 | 5 | 4 | — | — | 12 |
Lymphoid leukemia | D007945 | — | C91 | 3 | 5 | 4 | — | — | 12 |
Lymphoma | D008223 | — | C85.9 | 5 | 5 | 2 | — | — | 11 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 3 | 1 | — | — | 7 |
B-cell lymphoma | D016393 | — | — | 2 | 2 | 1 | — | — | 5 |
Pemphigus | D010392 | EFO_1000749 | L10 | — | — | 1 | — | — | 1 |
Follicular lymphoma | D008224 | — | C82 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | — | 1 | 1 |
Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | — | — | — | 1 | 1 |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 1 | 1 |
Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
Optical coherence tomography | D041623 | — | — | — | — | — | — | 1 | 1 |
Retinal degeneration | D012162 | — | — | — | — | — | — | 1 | 1 |
Visual acuity | D014792 | — | — | — | — | — | — | 1 | 1 |
Atrophy | D001284 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Ofatumumab |
INN | ofatumumab |
Description | Immunoglobulin G1, anti-(human CD20 (antigen))(human monoclonal HuMax-CD20 heavy chain), disulfide with human monoclonal HuMax-CD20 kappa-chain, dimer |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | >3GIZ:H|Fab fragment of anti-CD20 antibody Ofatumumab, heavy chain
EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLY
LQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPGSSKSTSGTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP
>3GIZ:L|Fab fragment of anti-CD20 antibody Ofatumumab, light chain
EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEP
EDFAVYYCQQRSNWPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR |
PDB | 3GIZ, 6Y92 |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1201836 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB06650 |
UNII ID | M95KG522R0 (ChemIDplus, GSRS) |